Candel Therapeutics (CADL) Cash & Equivalents (2020 - 2025)

Candel Therapeutics' Cash & Equivalents history runs 6 years deep, the most recent figure standing at $119.7 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 16.64% year-over-year to $119.7 million; the TTM figure through Dec 2025 stood at $119.7 million (up 16.64% YoY), while the FY2025 annual figure was $119.7 million, up 16.64% from the prior year.
• Cash & Equivalents came in at $119.7 million for Q4 2025 at Candel Therapeutics, up from $87.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $119.7 million in Q4 2025 to a low of $16.6 million in Q3 2024.
• A 5-year average of $67.3 million and a median of $77.2 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 61.48% in 2024 and surged 425.2% in 2025, its largest moves.
• Candel Therapeutics' Cash & Equivalents stood at $82.6 million in 2021, then decreased by 15.23% to $70.1 million in 2022, then plunged by 49.45% to $35.4 million in 2023, then jumped by 189.88% to $102.7 million in 2024, then grew by 16.64% to $119.7 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $119.7 million, $87.0 million, and $100.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison